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Abstract
Background: Although there are many therapeutic options to manage patients with sacrococcygeal pilonidal sinus
disease, there remains controversy over a gold standard method for treating such patients. Most studies regarding
sacrococcygeal pilonidal sinus, collected patients in a single pool, and single modality was performed to all patients
so far. Staging according to the progressive nature of disease and comparisons of stage-based treatment
approaches are yet to be conducted. This study aimed to define a staging system and to evaluate outcomes with
the use of stage-based treatment approach.
Methods: The collected data of patients who underwent surgery for the treatment of pilonidal sinus disease prior
to June 2011 were analyzed. Following this analysis, a staging system was defined based on morphological extent
of disease (stage I to stage IV for primary disease, and stage R for recurrent disease). Specific surgical technique was
used for each stage. Between June 2011 and December 2014, 367 patients were operated based on proposed
staging system and treatment algorithm. Demographics, perioperative data, short-term and long-term outcomes
were evaluated according to the disease stage.
Results: For all patients, the median length of hospital stay was 1 (range, 0–4) day. Primary healing without any
wound complications was achieved in 320 (87.2 %) patients. The median time to functional recovery was 10 (range,
2–35) days and for wound healing was 12 (range, 10–55) days. Disease recurrence was identified in six (1.6 %)
patients within the median follow-up period of 29 (range, 5–47) months. The outcomes of each stage were
evaluated separately.
Conclusions: We believe that the proposed staging system and stage-based treatment approach, which need
further validation, will have an efficacy in the treatment of chronic pilonidal sinus disease and will contribute to the
development of more appropriate individualized management approaches. Moreover, the use of this staging
system will likely facilitate sharing and comparing more specific clinical data from future studies.
Trial registration: NCT02712970 (ClinicalTrials.gov/09.03.2016)
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Background
Sacrococcygeal pilonidal sinus disease (PSD) is a com-
mon condition that predominantly affects young adults
[1]. Although it is clinically asymptomatic in some cases,
PSD may also present as a chronic, complicated disease,
characterized by multiple sinus tracts, leading to severe
impairment of patient quality of life. The heterogeneous
nature of PSD presentation has been associated with the
progressive course of pilonidal sinus development [2].
During the period of chronic abscess and epithelial tube
development from normal hair follicles, the disease may
affect more than one follicle and lead to lateral fistuliza-
tion outside the midline [3].
To date, several studies have been conducted to deter-
mine the most appropriate treatment strategy for PSD
[4–6]. Despite the heterogeneous nature of the disease,
in most of the previous studies, all patients were col-
lected in a single pool and a single treatment protocol
was performed to all patients without grouping the pa-
tients and without considering the extent of the disease
severity. These studies have provided data regarding a
number of outcomes in these heterogeneous patient
groups, including healing time (range, 1–78 weeks), time
to return to work (range, 2–77 days), length of hospital
stay (range, 2–14 days), and recurrence rates (range,
0 %–21 %) [4, 5, 7–9]. The application of a single treat-
ment approach to all included trial patients has the po-
tential to be harmful because it may contradict the “less
is more” concept, causing cases with previously limited
disease to progress to larger tissue defects [10]. Al-
though the previously recommended classification sys-
tems have categorized the disease into several groups,
staging according to the risk of disease progression is yet
to be achieved [11, 12]. Further, direct comparisons of
stage-based treatment approaches are yet to be
conducted.
In this study, we aimed to propose a staging system in
accordance with the progressive nature of pilonidal sinus
disease. Moreover, we presented the results of patients
treated with stage-based treatment approach that was
suggested for each stage.
Methods
This study was conducted at the Trabzon Kanuni
Training and Research Hospital, a high-volume center
for PSD and ethical approval was received from the In-
stitutional Ethics Committee. The disease stages were
determined from the database of patients who under-
went surgery for the treatment of PSD prior to June
2011. Demographic data, preoperative and operative
photographs, preoperative ultrasonographic images if
done, and histology reports of excised specimens were
analyzed. Following this analysis, a staging system (Stage
I–IV) was defined as follows by using morphological ex-
tent of the disease:
Stage I: Single pit in the midline, no lateral extension
Stage II: >1 pits in the midline, no lateral extension
Stage IIa: 2–3 pits in the midline
Stage IIb: >3 pits in the midline
Stage III: Midline pit/pits plus lateral extension in one
direction
Stage IV: Midline pit/pits plus lateral extension in both
directions
(Stage R: Recurrent PSD following any type of
treatment)
PSD which identified incidentally and which presented
with acute abscesses were not included to the staging
system. Moreover, patients with recurrent disease were
included as a separate group, Stage-R. Specific surgical
technique was used for each stage except for stage-R.
The technique was decided based on the potential defect
size following the excision of the diseased tissue. Ac-
cording to our algorithm, “pit-picking” technique was
performed under local anesthesia on an outpatient basis
in stage I and stage IIa patients [13]. In pit-picking tech-
nique, midline pits were excised removing a minimal
amount of tissue (with a margin of skin of <1mm). Inci-
sion of 1-2 cm in length was performed parallel to the
most convenient side of the midline to be curetted of
the chronic abscess cavity. All infected granulation tissue
and hair were removed. After establishing hemostasis,
the area of the excised midline pits was approximated by
absorbable sutures. No specific postoperative wound
care was given. For stage IIb and stage III patients, the
Bascom Cleft Lift (BCL)/modified Bascom Cleft Lift
(MBCL) techniques were performed [14, 15]. For stage
IV patients, the rhomboid excision with the Limberg flap
technique was used [16]. The BCL/MBCL/Limberg flap
techniques that were described previously in detail, were
performed under spinal anesthesia. The schematic repre-
sentations of the proposed staging groups and surgical
interventions that we recommend for each stage are
shown in Fig. 1.
We prospectively collected data on patients undergo-
ing surgery consecutively between June 2011 and De-
cember 2014. Surgical treatment was only recommended
to symptomatic patients with the complaints of dis-
charge or history of abscess drainage. Patients younger
than 18 years of age and patients who were treated with-
out the use of the suggested algorithm (operated by
other surgical teams) were excluded from the analysis.
Proposed algorithm was described in detail to all pa-
tients and written informed consent were obtained from
patients. Prophylactic, preoperative antibiotics were ad-
ministered to all patients. Drains were used according to
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the surgeon’s preference. Data regarding patient demo-
graphics, duration of symptoms, previous treatments,
operative data, length of hospital stay, primary healing
rate, functional recovery time, wound healing time,
complications, and recurrence for 367 patients were
analyzed.
Follow-up visits were on postoperative days 3, 10, and
30 and every 6 months thereafter by either follow-up
visits or by phone. All patients were examined by a
surgeon during follow-up period. Complications were
classified as infection (superficial or deep), collection
(seroma or hematoma), wound dehiscence (partial or
complete), or anesthesia-related complications. All surgi-
cal site complications were recorded, and patients with
prolonged healing were regularly examined until
complete healing was achieved. Primary healing was de-
fined as no breakdown of the wound (complication-free
healing) at any point along its length. The patients were
asked when they felt comfortable about starting their
daily activities and the interval between surgery and re-
turn to daily activities was defined as functional recovery
time. Recurrence was used when symptoms of the dis-
ease recurred some time after complete wound healing.
All parametric data values were presented as mean ±
standard deviation and non-parametric data values were
presented as median (range).
Results
The majority of the 367 patients who underwent surgery
according to our proposed staging system presented
with stage II disease (43.3 %). 71 patients (19.4 %) were
classified as stage-I and all were operated because of the
symptoms such as bleeding or purulent discharge even
they have only one midline pit. No patient required add-
itional intervention other than the recommended tech-
niques in Fig. 1. Of the 367 included patients, 273
(74 %) were male and 94 (26 %) were female. The me-
dian age was 22 (range, 18–47) years, and the median
body mass index was 23.6 (range, 18.2–41.6). The me-
dian duration of symptoms was 12 (range, 1–120)
months, and 39 (10.6 %) patients had a history of ab-
scess drainage. The duration of symptoms for each stage
are shown in Fig. 2.
The median operative duration was 28 (range, 6–48)
min. Surgical drains were used in 93 (25.3 %) patients,
and the median time for drain removal was 1 (range, 1–
3) day. The median length of hospital stay was 1 (range,
0–4) day. Demographic and perioperative patient data
according to the disease stages are presented in Table 1.
Primary healing without any wound complications was
achieved in 320 (87.2 %) patients. Infection was observed
in 20 (5.4 %, all superficial) patients, seroma in 28
(7.6 %), and partial dehiscence in 14 (3.8 %). The median
time to functional recovery was 10 (range, 2–35) days
and for wound healing was 12 (range, 10–55) days. In
patients with complicated wounds, the median time for
functional recovery and complete wound healing were
12 days and 18 days, respectively. Disease recurrence
was identified in six (1.6 %) patients within the median
follow-up period of 29 (range, 5–47) months. The short-
term and long-term patient outcomes according to dis-
ease stages are presented in Table 2.
Discussion
In the present study, cases of PSD which is a progressive
disease were classified according to the disease stage,
and the patient outcomes following the use of a surgical
treatment approach based on the disease stage were
evaluated. Favorable primary healing rates and earlier
functional recovery with acceptable morbidity was ob-
tained for all disease stages, particularly in cases of early
disease stages where limited surgery was performed.
Fig. 1 The schematic representations of the proposed staging groups and recommended surgical interventions for each stage
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While stage II was the most frequent presentation type
in the present study, extensive disease, defined as stage
IV, was observed in only 5 % of the included patients.
Moreover, a correlation between symptom duration and
disease stages was determined by this study.
Clinical trials for PSD aim to identify simple and low-
cost treatment approaches that require short hospital
stays, decreased use of dressings, earlier recovery, and
minimal impact on patient quality of life [17, 18].
However, despite studies being conducted for over a
century, a gold standard technique for the treatment of
PSD is yet to be defined. We believe the underlying
cause of this failure to define the most appropriate treat-
ment technique as the heterogeneous nature of the dis-
ease. Attempts to treat such heterogeneous clinical
conditions with a single technique are unlikely to be the
optimal approach. Therefore, the development of a PSD
staging system is essential for decision-making processes
Fig. 2 Median values of the symptom duration for each stage
Table 1 Demographics and perioperative outcomes according to the disease stages
All (n:367) Stage-I (n:71) Stage-II (n:159) Stage 2a (n:31)
Stage 2b (n:128)
Stage-III (n:78) Stage-IV (n:19) Stage-R (n:40)
Age (years) 22 (18–47) 23 (18–47) 22 (18–45) 2a: 19 (18–26)2b: 22 (18–45) 23 (18–45) 22 (18–24) 25 (18–46)
Sex
Male 273 (74.4 %) 57 (80.3 %) 117 (73.6 %) 2a: 19 (61 %)2b: 98 (77 %) 52 (66.7 %) 19 (100 %) 28 (70 %)
Female 94 (25.6 %) 14 (19.7 %) 42 (26.4 %) 2a: 12 (39 %)2b: (23 %) 26 (33.3 %) - 12 (30 %)
Body mass
index (kg/m2)
23.6 (18.2–41.6) 24.2 (19.8–32) 24.9 (18.2–41.6) 2a: 25 (21.5–29.4)2b: 24
(18.2–41.6)








39 (10.6 %) 2 (2.8 %) 6 (3.8 %) 2a: 1 (3 %)2b: 5 (4 %) 22 (28.2 %) 5 (26.3 %) 4 (10 %)
Operative
duration (minutes)
28 (6–48) 8 (6–11) 28 (6–47) 2a: 8 (6–9)2b: 30 (21–47) 29 (20–47) 44 (38–45) 33 (26–48)
Drain usage (n) 93 (25.3 %) 0 19 (11 %) 2a:02b: 19 (15 %) 28 (35.9 %) 19 (100 %) 27 (67.5 %)
Drain removal
time (days)
1 (1–3) 0 1 (1–2) 2a: 02b: 1 (1–2) 1 (1–3) 1 (1–3) 1 (1–3)
Hospital stay (days) 1 (0–4) 0 1 (0–3) 2a:02b: 1 (1–3) 1 (1–4) 2 (1–4) 1 (1–3)
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regarding the management of this disease. Disease sta-
ging allows the use of more specific treatment strategies
and estimation of prognosis. Further, it facilitates data
sharing among investigators, thus enabling comparison
of the results, quality, and cost of studies and may allow
clinical studies to be performed in more specific patient
groups. In the present study, four stages of chronic PSD
were defined according to the degree of disease progres-
sion. The developed staging system informed the appli-
cation of differing treatment modalities for different
disease stages, with variable clinical outcomes obtained
for each disease stage. For early disease stages, early re-
covery was obtained with patients returning to work
within a few days. However, no increase in recovery time
was observed in patients with late disease stages because
of the extent of surgery and an increased incidence of
wound complications. The comparisons of outcomes be-
tween disease stages were not performed. We believe
that short-term and long-term outcomes should be eval-
uated separately according to a stage-based approach.
The use of this disease staging system will likely facilitate
sharing and comparing more specific clinical data from
future studies, thus contributing to the development of
individualized patient management strategies.
Unlike primary PSD, it is not feasible to determine dis-
ease severity or stage in case of recurrent PSD by evalu-
ating the initial appearance of the gluteal area [19, 20].
Many factors, including morphological changes resulting
from previous surgical procedures, time since previous
surgery, development of new disease whether over previ-
ous surgical incision or not, and distinguishing recur-
rence and unhealed wounds, have an effect on the
choice of treatment for recurrent disease. Therefore, it is
unlikely that all recurrent cases can be appropriately
managed with a single method of surgical intervention.
Thus, we believe that a recurrent disease requires an in-
dividualized classification system. In the presented sta-
ging system, recurrent cases were classified as a separate
group and were treated with a range of techniques.
While asymptomatic disease is generally found inciden-
tally, prophylactic surgery is universally considered to be
of no benefit and we, therefore, chose not to include
asymptomatic disease in our staging system [21]. Fur-
thermore, acute abscess formation may develop at any
stage of PSD and does not require the use of specific
treatment approaches [22]. Therefore, we limited the de-
veloped staging system to primary chronic symptomatic
disease only.
Stage I and stage II PSD are generally the earliest
forms of symptomatic disease to present. While most
cases of PSD begin as a single-pit disease arising from a
single follicle, inflammation develops in other follicles
over time because of the ongoing effect of predisposing
factors previously described by Karydakis and Bascom
[23–25]. At later stages, the involved follicles fistulize ei-
ther unilaterally or bilaterally to areas outside the mid-
line. Although the majority of surgical/non-surgical
treatment methods can be used for all stages of the dis-
ease, various clinical experiences and habits among phy-
sicians have led to the development of a number of
treatment approaches for PSD [26, 27]. Based on our
previously published experiences, BCL/MBCL have be-
come the preferred method for stage II/III disease in our
practice [15, 28]. However, because this is an aggressive
approach for stage I disease, we prefer the less invasive
method, “pit-picking,” which can be performed under
local anesthesia on an outpatient basis in cases of stage I
disease. Further, we favor the “rhomboid excision with
Limberg flap” technique in cases of stage IV disease,
which enables wider tissue excision bilaterally and has
favorable clinical outcomes [29]. In the developed algo-
rithm, the extent of disease in stage II patients is deter-
mined by the number of pits located in the midline.
Although it is possible to perform the pit-picking tech-
nique in patients with greater numbers of pits (up to
10), we limited the use of this technique in the present
Table 2 Short-term and long-term outcomes according to disease stage
All (n:367) Stage-I (n:71) Stage-II (n:159) Stage 2a (n:31)Stage 2b (n:128) Stage-III (n:78) Stage-IV (n:19) Stage-R (n:40)
Anesthesia
complication (n)
9 (2.5 %) 0 3 (1.9 %) 2a: 02b: 3 (2.3 %) 4 (5.1 %) 2 (10.5 %) 0
Wound complications (n)
Infection 20 (5.4 %) 0 10 (6.3) 2a: 2 (6.5 %)2b: 8 (6.3 %) 6 (7.7 %) 2 (10.5 %) 2 (5 %)
Collection 28 (7.6 %) 2 (2.8 %) 7 (4.4 %) 2a: 3 (9.7 %)2b: 4 (3.1 %) 11 (14.1 %) 2 (10.5 %) 6 (15 %)
Dehiscence 14 (3.8 %) 0 4 (2.5 %) 2a:02b: 4 (3.1 %) 5 (6.4 %) 1 (5.3 %) 4 (10 %)
Primary healing (n) 320 (87.2 %) 69 (97.2 %) 143 (89.9 %) 2a: 27 (87.4 %)2b: 116 (90.6 %) 62 (79.5 %) 16 (84.2 %) 30 (75 %)
Functional recovery
time (days)
10 (2–35) 4 (2–7) 10 (2–35) 2a: 4 (2–7)2b: 12 (7–35) 12 (7–25) 12 (10–14) 12 (8–22)
Wound healing time
(days)
12 (10–55) 20 (12–35) 12 (10–55) 2a: 22 (12–30)2b: 10 (10–35) 12 (10–40) 14 (12–20) 12 (10–22)
Recurrence (n) 6 (1.6 %) 0 1 (0.6) 2a: 1 (3.2 %)2b: 0 2 (2.6 %) 1 (5.3 %) 2 (5 %)
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algorithm to patients with up to three pits because of a
relatively high recurrence and reoperation rates of the
pit-picking technique when used in all patients, regard-
less of disease extent [13, 30–33]. We therefore reserved
the use of BCL/MBCL techniques for patients with
greater numbers of pits. We believe this limitation en-
abled the low recurrence rates in patients that under-
went pit-picking in the current study. While there was
no recurrence in stage I patients, recurrence occurred in
one stage IIa patient who had an uneventful postopera-
tive period before the development of a new pit eight
months after the pit-picking procedure. The higher rates
of recurrence observed in patients with more than one
pit supports our decision not to include patients with 1–
3 pits in stage I and to divide stage II into two distinct
subgroups. When determining the appropriate manage-
ment for PSD, the risk/benefit ratio of the preferred mo-
dality regarding the speed of recovery and recurrence
rates should be carefully considered an on individual
basis.
To the best of our knowledge, the present study is the
first staging system and stage-based treatment approach
for PSD. However, this staging system has some limita-
tions. Because PSD is present in a hidden anatomical
area and can have an asymptomatic course, there are no
validated methods for determining disease onset and
progression. To overcome this, we used the data of pa-
tients who underwent surgical treatment prior to the be-
ginning of the study to define disease stages. In the
present study, we demonstrated a correlation between
disease severity and duration of symptoms. We did not
evaluate patient-related anthropometrics (body mass
index, depth of intergluteal sulcus, thickness of fat tissue
etc.) which probably have impact on the treatment out-
comes. In future studies, anthropometrics should be in-
cluded in the staging system; however, the addition of
these factors could negatively affect the application of
the staging system by increasing the complexity and
making the algorithm more difficult to remember. The
lack of cost analysis and the lack of comparison of cos-
metic outcomes are other limitations of the present
study. Besides, we used potential defect size as a deter-
mining factor to select the surgical treatment method.
However, we know that various methods could be used
for the treatment of PSD. In the future, studies compar-
ing various techniques including surgical or non-surgical
treatment methods for each disease stage are required to
determine the most appropriate strategy.
Conclusions
Chronic symptomatic PSD is a progressive disease that
mainly affects young adults and is a significant cause of
work loss. The identification of a single treatment ap-
proach for PSD has proved to be challenging because of
the heterogeneous nature of clinical presentations in
cases of PSD. Therefore, a more feasible approach may
be to identify strategies for “the best management” ra-
ther than “the best technique” in future clinical studies.
While it would be possible to define various staging sys-
tems and algorithms, the presented staging system
showed acceptable morbidity and recurrence rates for all
disease stages. We believe that the proposed staging sys-
tem and stage-based treatment approach, which need
further validation, will have an efficacy in the treatment
of chronic pilonidal sinus disease and will contribute to
the development of more appropriate individualized
management approaches. Moreover, the use of this sta-
ging system will likely facilitate sharing and comparing
more specific clinical data from future studies.
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